USA - NASDAQ:OPCH - US68404L2016 - Common Stock
The current stock price of OPCH is 26.03 USD. In the past month the price decreased by -5.35%. In the past year, price increased by 7.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.41 | 99.12B | ||
| CI | THE CIGNA GROUP | 8.6 | 65.24B | ||
| LH | LABCORP HOLDINGS INC | 16.05 | 21.10B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 200.69 | 19.55B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.03 | 19.67B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.35 | 15.75B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.60B | ||
| HIMS | HIMS & HERS HEALTH INC | 56.83 | 10.27B | ||
| DVA | DAVITA INC | 12.27 | 8.51B | ||
| CHE | CHEMED CORP | 19.6 | 6.28B | ||
| RDNT | RADNET INC | 211.08 | 5.85B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 60.09 | 5.85B |
Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The company is headquartered in Bannockburn, Illinois and currently employs 6,015 full-time employees. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. The company provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. The company administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
OPTION CARE HEALTH INC
3000 Lakeside Dr, Suite 300N
Bannockburn ILLINOIS 60015 US
CEO: John C. Rademacher
Employees: 7052
Phone: 13129402443
Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The company is headquartered in Bannockburn, Illinois and currently employs 6,015 full-time employees. The Company’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. The company provides a therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. The company administers a wide variety of therapies and services, including anti-infectives infusion, nutrition support, immunoglobulin infusion, chronic inflammatory disorders, neurological disorders, bleeding disorders infusion, Naven health, women’s health, heart failure, and others. Its home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement.
The current stock price of OPCH is 26.03 USD. The price decreased by -0.67% in the last trading session.
OPCH does not pay a dividend.
OPCH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
OPCH stock is listed on the Nasdaq exchange.
ChartMill assigns a fundamental rating of 6 / 10 to OPCH. OPCH scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months OPCH reported a non-GAAP Earnings per Share(EPS) of 1.49. The EPS increased by 25.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.93% | ||
| ROA | 6.24% | ||
| ROE | 15.53% | ||
| Debt/Equity | 0.81 |
16 analysts have analysed OPCH and the average price target is 38.42 USD. This implies a price increase of 47.6% is expected in the next year compared to the current price of 26.03.
For the next year, analysts expect an EPS growth of 42.55% and a revenue growth 13.85% for OPCH